A real life retrospective analysis of drug expenditure reveals no significant cost difference between infliximab and adalimumab in the treatment of adult crohn's disease
Lamb, C. A., Price, M., Robinson, M., Gunn, M. C., Thompson, N. P., Mansfield, J. C.Volume:
60
Language:
english
Journal:
Gut
DOI:
10.1136/gut.2011.239301.534
Date:
April, 2011
File:
PDF, 89 KB
english, 2011